While a great deal has been learned about the genetic control of B lymphocyte behavior through the observation of primary B cells from mice bearing targeted gene mutations, such studies can be restricted by the limited number and longevity of the cells ex vivo, by their heterogeneity, and by the inability to apply further genetic manipulations. Here we describe a protocol for the efficient derivation of mutant B lymphoma cell lines, by crossing mice bearing targeted mutations in genes affecting mature B cell function with transgenic mice bearing the lymphomagenic Emu-myc transgene. Pre-B and B lymphomas were obtained with high frequency, and the cells were readily adaptable to culture. The B lymphoma lines bore surface markers consistent with an immature phenotype and were amenable to cloning and to stable transfection. They are currently being used as a well-defined and unlimited cell source to study antigen receptor signalling and B cell-specific gene regulation, and the dependence of these processes on the products of the vav, CD45, lyn, oct-2, btk and OBF-1 genes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0022-1759(99)00094-0 | DOI Listing |
Antimicrob Agents Chemother
January 2025
Univ. of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, Lille, France.
Self-transmissible IncC plasmids rapidly spread multidrug resistance in many medically important pathogens worldwide. A large plasmid of this type (pIP1202, ~80 Kb) has been isolated in a clinical isolate of , the agent of plague. Here, we report that pIP1202 was highly stable in infected mice and fleas and did not reduce virulence in these animals.
View Article and Find Full Text PDFBioconjug Chem
January 2025
Department of Chemistry, Washington State University, Pullman, Washington 99164, United States.
Monomethyl auristatin E (MMAE) is a promising treatment option for patients diagnosed with prostate cancer (PCa); however, toxicities prevent MMAE from being administered as free drug. No MMAE-based treatment is currently marketed for PCa. Herein, we describe a small-molecule-drug conjugate, CTT2274, for the selective delivery of MMAE.
View Article and Find Full Text PDFInt J Pharm
January 2025
The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, No.157 Xiwu Road, Xi'an, Shaanxi 710004, China. Electronic address:
Both photothermal therapy (PTT) and chemodynamic therapy (CDT) are designed to focus their antitumor effect on only the tumor site, thereby minimizing unwanted severe damage to healthy tissue outside the tumor. However, each monotherapy is limited in achieving complete tumor eradication, resulting in tumor recurrence. The combination of multiple therapies may help to overcome the limitations of single therapy, improve the chances of complete tumor eradication, and reduce the risk of recurrence.
View Article and Find Full Text PDFJ Biol Chem
January 2025
Cell and Molecular Biology Laboratory, Department of Zoology, University of Kalyani, Kalyani, Nadia, West Bengal, India, 741235. Electronic address:
Aberrant activation of the hedgehog (Hh) signaling pathway positively correlates with progression, invasion and metastasis of several cancers, including breast cancer. Although numerous inhibitors of the Hh signaling pathway are available, several oncogenic mutations of key components of the pathway, including Smoothened (Smo), have limited their capability to be developed as putative anti-cancer drugs. In this study, we have modulated the Hh signaling pathway in breast cancer using a specific FDA-approved phosphodiesterase 4 (PDE4) inhibitor rolipram.
View Article and Find Full Text PDFPharmacol Res
January 2025
Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, China. Electronic address:
T-cell lymphomas (TCLs) are heterogeneous malignancies with limited treatment options and poor outcomes. The efficacy of traditional T-cell therapies, including chimeric antigen receptor (CAR) T cells, is often constrained by immunosuppressive factors and the tumor microenvironment. On the other hand, although direct Granzyme B (GrB) administration can effectively induce tumor cell apoptosis, it lacks universal tumor targeting and efficient cellular entry mechanisms.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!